NRC
NRC Health
20.40$
-5.7%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +0.1% | -7.1% | -0.8% | +2.3% | +3.0% | -9.1% | +1.5% | +1.7% | +1.7% | -1.1% | +1.7% | – | |
| – | -5.7% | +0.5% | -3.1% | +14.0% | -6.2% | +1.7% | +0.8% | -0.8% | +10.2% | -1.7% | -14.2% | – | |
| – | +3.8% | -11.4% | +0.7% | -5.0% | +10.0% | -16.0% | +2.0% | +3.6% | -4.5% | -0.6% | +86.4% | – | |
| – | -6.2% | +1.6% | -0.3% | -2.1% | +4.2% | -9.6% | +71.2% | -30.8% | +17.7% | -7.1% | +71.0% | – | |
| – | -6.4% | +1.6% | +0.3% | -1.6% | +3.5% | -20.1% | +71.2% | -30.8% | +17.7% | -7.1% | +187.9% | – | |
| – | +17.6% | -25.2% | +1.2% | -10.0% | +20.2% | -10.3% | -81.5% | +387.2% | -39.7% | +19.3% | -158.1% | – | |
| – | +67.5% | +125.7% | -8.3% | +27.2% | +3.3% | +23.3% | +14.8% | +41.6% | -6.2% | -8.4% | +5.3% | – | |
| – | +14.2% | -28.5% | +1.6% | -12.3% | +21.6% | -13.0% | -92.5% | +979.5% | -47.9% | +34.0% | -203.6% | – | |
| – | +20.7% | -29.7% | +17.1% | -25.2% | +44.0% | -16.4% | -64.5% | +213.1% | -31.6% | -21.3% | -208.4% | – | |
| – | +12.5% | -28.2% | -2.9% | -7.9% | +15.3% | -11.8% | -101.8% | – | -56.4% | +79.3% | -201.9% | – | |
| – | +12.0% | -22.2% | +1.4% | -8.1% | +16.5% | -8.6% | -67.0% | +195.9% | -31.7% | +15.0% | -114.0% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.